Cardiac dysfunction is a broad term describing any condition in which the heart cannot pump blood or fill with blood as effectively as it should. The problem can sit on either side of the heartbeat: the squeezing phase, the relaxing phase, or both. Because the heart supplies oxygen to every organ, even modest drops in its performance can ripple outward into fatigue, fluid buildup, and shortness of breath. The causes range from blocked arteries and chronic high blood pressure to viral infections and certain cancer drugs, and the treatment landscape has expanded considerably over the past two decades.
Two Broad Categories of Dysfunction
Cardiologists generally split cardiac dysfunction into two types based on what goes wrong during each heartbeat. In systolic dysfunction, the heart muscle loses its ability to contract forcefully enough, so less blood gets pushed out with each beat. This shows up as a reduced ejection fraction, the percentage of blood the left ventricle ejects per contraction, and an enlarged heart chamber. In diastolic dysfunction, the heart squeezes adequately but has trouble relaxing and filling. The chamber walls become stiff, and pressure inside the heart rises even though the ejection fraction looks normal or close to it.1PubMed. Differentiation between systolic and diastolic dysfunction These two patterns often coexist in the same patient, but distinguishing between them matters because the treatments differ.
The distinction extends to the right side of the heart as well. Right-sided heart failure has its own set of triggers, including lung diseases that raise pressure in the pulmonary arteries, congenital heart defects, and valve problems. Progressive right ventricular dysfunction worsens outcomes regardless of what originally caused it.2PubMed. Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association
What Causes Cardiac Dysfunction
Dozens of conditions can damage or weaken the heart. Some are slow-burning; others strike suddenly. Here are the most common categories.
Blocked Arteries and Heart Attacks
Coronary artery disease remains the leading cause of cardiac dysfunction worldwide. When a heart attack cuts off blood supply to part of the muscle, those cells die and are replaced by scar tissue. The surviving muscle has to work harder to compensate, and the heart’s shape and size begin to change in a process called adverse remodeling. This remodeling starts within days of the heart attack and can continue for up to a year, and it has been linked to poor long-term outcomes including progressive heart failure.3PubMed Central. Left Ventricular Adverse Remodeling in Ischemic Heart Disease: Emerging Cardiac Magnetic Resonance Imaging Biomarkers
Chronic High Blood Pressure
Years of elevated blood pressure force the heart to pump against higher resistance. The muscle thickens in response, a change called left ventricular hypertrophy. While the thickening is initially the body’s attempt to cope, it eventually becomes harmful. The thickened walls stiffen, impairing filling, and the heart’s electrical system becomes less stable. Left ventricular hypertrophy is an independent risk factor for atrial fibrillation, both systolic and diastolic heart failure, and sudden cardiac death.4PubMed Central. Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications
Inherited Cardiomyopathies
Genetic mutations can directly weaken the heart muscle or make it inappropriately thick. Researchers have identified mutations in genes that encode structural proteins inside heart cells, and even small changes can have outsized effects. For example, mutations in the TCAP gene, which encodes a protein involved in the mechanical scaffolding of heart muscle fibers, have been found in patients with both hypertrophic and dilated cardiomyopathy. The mutations alter how that protein interacts with its binding partners, tipping the balance toward either excessive thickening or dangerous thinning and stretching of the walls.5PubMed. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy TCAP is just one of many genes implicated; the broader point is that heart failure can run in families even in the absence of obvious risk factors like obesity or smoking.
Infections
Myocarditis, or inflammation of the heart muscle, is most commonly triggered by viral infections. A range of other organisms including bacteria, parasites, and fungi can also damage the heart, though viral causes dominate. People with weakened immune systems face additional risk from rare opportunistic pathogens that would not normally affect the heart.6PubMed Central. Infectious factors in myocarditis: a comprehensive review of common and rare pathogens Most cases of viral myocarditis resolve on their own, but a subset progress to chronic inflammation and lasting dysfunction.
Drugs and Toxins
Certain cancer chemotherapy drugs, especially the anthracycline class (which includes doxorubicin), are a well-recognized cause of heart damage. Anthracycline cardiotoxicity likely starts at the cellular level with direct injury to heart muscle cells and progresses through a drop in ejection fraction that, if caught too late, can lead to full-blown heart failure.7PubMed Central. Cardiotoxicity of Anthracyclines The damage involves the generation of harmful reactive oxygen species and disruption of an enzyme called topoisomerase 2 inside the heart cells.8PubMed Central. Anthracycline Chemotherapy and Cardiotoxicity Because these drugs are effective against many cancers, they cannot simply be avoided; instead, oncologists and cardiologists work together to monitor heart function throughout treatment and intervene early if signs of damage appear.
Heavy alcohol use over years is another common toxic cause, producing a pattern sometimes called alcoholic cardiomyopathy. And recreational drugs, particularly stimulants, can trigger acute damage or accelerate chronic decline.
Stress Cardiomyopathy
Takotsubo cardiomyopathy, often called “broken heart syndrome,” illustrates how powerfully the nervous system can affect the heart. It occurs when a surge of stress hormones, triggered by intense emotional or physical stress, temporarily stuns the heart muscle. During the acute phase, circulating levels of epinephrine and norepinephrine spike dramatically, causing direct toxicity to heart cells, spasm of the coronary arteries, and a distinctive ballooning of the lower left ventricle.9PubMed. Pathophysiology of Takotsubo Syndrome Most patients recover within weeks, but the condition can be life-threatening in the acute setting and recur in some people.
How the Body Responds, and Why That Response Backfires
When the heart’s output drops, the body does not sit idle. It activates two powerful emergency systems: the sympathetic nervous system (the “fight or flight” response) and the renin-angiotensin-aldosterone system, which regulates blood pressure and fluid balance. In the short term, these systems prop up blood pressure by speeding the heart rate, tightening blood vessels, and retaining salt and water. The problem is that these systems evolved for short bursts of stress. When they stay switched on for weeks or months, they place extra strain on an already struggling heart, damage blood vessels, and promote harmful remodeling of the heart muscle itself.10PubMed Central. Neurohormonal activation in heart failure with reduced ejection fraction11PubMed. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure This insight is the foundation for most modern heart failure medications, which work by dialing these overactive systems back down.
At the cellular level, the failing heart also develops problems with calcium handling. Calcium is the signal that tells heart muscle fibers to contract, and its precise cycling in and out of storage compartments inside the cell is what keeps each heartbeat synchronized. In heart failure, the machinery that stores and releases calcium becomes dysfunctional, leading to weaker contractions, incomplete relaxation, and even dangerous arrhythmias.12PubMed Central. Ca handling during excitation-contraction coupling in heart failure Meanwhile, changes in the connective tissue between heart cells alter the stiffness of the walls. An increase in the fibrous structural protein collagen, or more cross-linking between collagen fibers, makes the ventricle stiffer and harder to fill.13European Journal of Cardio-Thoracic Surgery. The relationship between myocardial extracellular matrix remodeling and ventricular function
How Cardiac Dysfunction Is Diagnosed
The most familiar test is an echocardiogram, which uses ultrasound to visualize the heart in real time. It can measure the ejection fraction, assess how well the walls are moving, and detect abnormal filling patterns. But echocardiography has its limits, particularly in patients with difficult-to-image body types or complex anatomy. In some cases, cardiac MRI provides a more complete picture. MRI-based techniques can quantify strain, meaning how much the heart muscle actually deforms with each beat, and these strain measurements have been shown to correlate with exercise capacity and symptom severity even when the ejection fraction looks acceptable.14PubMed. Value of speckle-tracking echocardiography and MRI-based feature tracking analysis in adult patients after Fontan-type palliation
Blood tests play an important supporting role. Two proteins released by stretched heart muscle cells, BNP and NT-proBNP, are widely used as markers for heart failure.15PubMed Central. BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine Elevated levels suggest the heart is under abnormal stress, though the numbers need to be interpreted alongside the patient’s age, kidney function, and body weight. NT-proBNP testing has proven especially useful in patients with high blood pressure, where it can help detect early diastolic dysfunction and left ventricular hypertrophy before symptoms become obvious.16PubMed Central. The Role of NT-proBNP Levels in the Diagnosis of Hypertensive Heart Disease
Medications for Reduced Ejection Fraction
For patients whose hearts are not squeezing strongly enough, current guidelines center on four drug classes used together. These are renin-angiotensin system inhibitors (which include a newer combination drug that also blocks neprilysin, an enzyme that breaks down beneficial hormones), beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. Each class works through a different mechanism, and the benefit is largest when all four are used in combination.17PubMed. Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction The recommendation rests on multiple large randomized trials, and all four classes show clinical benefit within about 30 days of starting.18PubMed Central. Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization
In practice, getting patients onto all four medications at effective doses is harder than it sounds. Each drug can cause side effects, from low blood pressure and dizziness with the renin-angiotensin inhibitors to fatigue with beta-blockers and electrolyte shifts with the mineralocorticoid antagonists. Cardiologists typically start one drug at a time, titrate the dose upward, and add the next class once the patient is tolerating the current regimen. This process can take weeks to months, and many patients never reach target doses because of tolerability issues, a gap that remains one of the biggest challenges in heart failure care.
When the Ejection Fraction Looks Normal
Heart failure with preserved ejection fraction, sometimes abbreviated HFpEF, has historically been the harder form to treat. For years, the medications that worked so well for reduced ejection fraction showed little benefit in these patients. That changed with the emergence of SGLT2 inhibitors, drugs originally developed for type 2 diabetes that turned out to have striking cardiovascular benefits. In randomized trials, SGLT2 inhibitors like dapagliflozin and empagliflozin reduced heart failure hospitalizations or cardiovascular death by roughly 20% compared with placebo in patients with preserved ejection fraction.19JAMA. Heart Failure With Preserved Ejection Fraction: A Review Beyond that, treatment focuses on managing symptoms, especially fluid overload, with diuretics and on aggressively controlling the conditions that drive the stiffness, particularly high blood pressure and obesity.
The Role of Metabolism
The heart is the most metabolically active organ in the body, and disruptions in how it generates energy can directly contribute to dysfunction. This connection is especially relevant in diabetes, where altered blood sugar and fat metabolism change the fuel mix the heart relies on. Virtually all major cardiovascular conditions are accompanied by shifts in cardiac substrate metabolism, and growing evidence suggests these metabolic changes are not merely a bystander effect but actively contribute to how the heart weakens over time.20Biochemical Journal. Cardiac substrate metabolism in type 2 diabetes This overlap between metabolic disease and cardiac dysfunction helps explain why SGLT2 inhibitors, which improve the metabolic environment, benefit the heart even in people without diabetes.
Device Therapies and Surgical Options
When medications alone are not enough, several device-based approaches can help. For patients with severely reduced ejection fraction and an abnormally wide electrical conduction pattern on their ECG, cardiac resynchronization therapy uses a specialized pacemaker to coordinate the timing of the left and right ventricles. A major trial found that adding resynchronization therapy to an implantable defibrillator reduced the combined risk of death or heart failure hospitalization by about 25% compared with the defibrillator alone, and cut deaths alone by a similar margin.21PubMed. Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure Adding a defibrillator component has been associated with lower mortality, particularly when the ejection fraction falls below 30%.22EP Europace. Cardiac resynchronization therapy with or without defibrillator in patients with heart failure
For end-stage heart failure, two options remain: a left ventricular assist device or heart transplantation. LVADs are mechanical pumps surgically implanted to help the weakened ventricle push blood forward. They were originally designed as a bridge to keep patients alive while awaiting a donor heart, but they are increasingly used as long-term therapy in patients who are not transplant candidates.23PubMed. Long-term use of a left ventricular assist device for end-stage heart failure Heart transplantation remains the only truly curative option for chronic heart failure, with roughly half of all recipients surviving beyond ten years. Yet the persistent shortage of donor organs means demand far exceeds supply, which has driven continued investment in LVAD technology and other alternatives.24PubMed Central. Heart transplantation and left ventricular assist device therapy: two comparable options in end-stage heart failure?
Exercise and Cardiac Rehabilitation
It might seem counterintuitive that a failing heart should be challenged with exercise, but structured cardiac rehabilitation is one of the most consistently beneficial interventions available. Programs that combine supervised exercise training with education, nutrition counseling, and psychological support improve exercise capacity, quality of life, and symptom burden. They also reduce heart-failure-related hospitalizations.25PubMed. Cardiac Rehabilitation for Patients With Heart Failure: JACC Expert Panel26PubMed Central. Evidence of Cardiac Rehabilitation for Heart Failure With Reduced Ejection Fraction in Recovery to Maintenance Phase Despite this evidence, referral and participation rates remain low. Many patients are never offered the option, and among those who are, barriers like transportation, cost, and time off work keep completion rates modest.
Socioeconomic Factors and Access
Cardiac dysfunction does not affect everyone equally. A large meta-analysis covering more than six million individuals found that low socioeconomic status was associated with a roughly 62% higher risk of developing heart failure compared with higher socioeconomic status, with the strongest associations seen for low income and low education level.27European Heart Journal – Quality of Care and Clinical Outcomes. Impact of socioeconomic status on incident heart failure and left ventricular dysfunction: systematic review and meta-analysis The reasons are layered: lower-income populations face higher rates of uncontrolled hypertension and diabetes, worse access to preventive care, greater exposure to environmental stressors, and more obstacles to filling prescriptions and attending follow-up appointments.28PubMed Central. Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions Areas with concentrated poverty and low educational attainment see worse heart failure outcomes even after adjusting for individual-level risk factors, suggesting that the neighborhood environment itself plays a role.29PubMed Central. Impact of Socioeconomic Status on Heart Failure
Gene Therapy and What May Come Next
The next frontier in treating cardiac dysfunction involves targeting the disease at the genetic level. Gene therapy for heart failure has been a research interest for years, and a phase 2 trial targeting SERCA2a, the pump responsible for pulling calcium back into storage inside heart cells, demonstrated that the approach was both safe and feasible.30PubMed Central. Gene therapy for heart failure While that particular trial did not produce the breakthrough efficacy results many had hoped for, it proved the concept that you could deliver genetic material to the human heart and alter its molecular behavior. More recent work has expanded the possibilities, with gene therapy and RNA-based treatments offering potential disease-modifying options for inherited cardiomyopathies and arrhythmias that currently have no cure.31PubMed. The Past, Present, and Future of Cardiac Gene Therapy32Cardiovascular Research. Gene therapy in cardiac and vascular diseases: a review of approaches to treat genetic and common cardiovascular diseases with novel gene-based therapeutics
These therapies are still early in development, and significant hurdles remain around delivery efficiency, immune reactions, and long-term safety. But for patients with genetic forms of cardiomyopathy who currently face a future defined by progressive decline, the prospect of a one-time treatment that corrects the underlying molecular defect is genuinely transformative. Several phase 1 trials are underway, and the field is moving faster now than at any point in the past two decades.